Nebert D W
Department of Pediatrics, University of Cincinnati Medical Center, Ohio 45267-0056, USA.
Clin Chem Lab Med. 2000 Sep;38(9):857-61. doi: 10.1515/CCLM.2000.124.
Individual risk of toxicity or cancer reflects the amount of exposure to environmental agents, combined with one's underlying genetic predisposition. More than six dozen human ecogenetic polymorphisms have been described; whereas some of these have been demonstrated to be associated with altered risks of toxicity or cancer, others presently remain equivocal and require further study. Thus, genetic differences in the regulation, expression and activity of "environmental susceptibility genes" can be decisive in defining susceptibility to toxicity or cancer. "Drug-metabolizing enzymes" (DMEs) are regarded as one class of environmental susceptibility genes. DME genes have actually existed on this planet for more than 2.5 billion years, and might more appropriately be named "effector-metabolizing enzymes." Receptors controlling DME levels have been called "DME receptors." DMEs have functioned in many critical life processes in prokaryotes and, more recently, in countless basic functions in plants and animals - events that evolved long before the existence of pharmaceutical companies and apothecaries. DME genes exist in every eukaryotic cell and probably in all prokaryotes. Virtually all environmental agents act as either agonists or antagonists - in competing with endogenous ligands that bind to DME receptors and/or competing as substrates for the DMEs. Over the past decade it has become clear that each of us has our own "individual fingerprint" of unique alleles coding for DMEs. The underlying genetic predisposition of each patient will reflect combinations of poor- and extensive-metabolizer phenotypes; if these enzymes cooperate in the same metabolic pathway for any given drug or environmental agent, such ecogenetic variability might be synergistic and lead to as much as 30- or >40-fold differences in activation or degradation. The end result can be large interindividual differences in risk of environmentally caused toxicity or cancer.
个体发生毒性反应或患癌风险反映了接触环境因子的量,以及个体潜在的遗传易感性。已描述了超过六十几个人类生态遗传多态性;其中一些已被证明与毒性反应或患癌风险的改变有关,而其他一些目前仍不明确,需要进一步研究。因此,“环境易感性基因”在调控、表达和活性方面的遗传差异在确定对毒性反应或癌症的易感性方面可能起决定性作用。“药物代谢酶”(DMEs)被视为一类环境易感性基因。实际上,DME基因在这个星球上已经存在了超过25亿年,或许更应被命名为“效应物代谢酶”。控制DME水平的受体被称为“DME受体”。DMEs在原核生物的许多关键生命过程中发挥作用,最近,在植物和动物的无数基本功能中也发挥作用——这些事件早在制药公司和药剂师出现之前就已进化。DME基因存在于每个真核细胞中,可能也存在于所有原核生物中。几乎所有环境因子都作为激动剂或拮抗剂起作用——与结合到DME受体的内源性配体竞争和/或作为DMEs的底物竞争。在过去十年中,已经清楚的是,我们每个人都有自己独特的DME编码等位基因的“个体指纹”。每个患者的潜在遗传易感性将反映代谢不良和代谢广泛表型的组合;如果这些酶在任何给定药物或环境因子的同一代谢途径中协同作用,这种生态遗传变异性可能具有协同作用,并导致激活或降解方面高达30倍或>40倍的差异。最终结果可能是个体在环境所致毒性反应或患癌风险方面存在很大差异。